SCHEMBL6396129

SCHEMBL6396129

Cc1c(C=C2C(=O)Nc3ccccc32)[nH]c2ccccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 9/20 0.64
AURKB Q96GD4 5/20 0.61
CDK7 P50613 2/20 0.61
CDK5 Q00535 2/20 0.61
CDK1 P06493 2/20 0.61
CCNB1 P14635 1/20 0.61
CCNA2 P20248 1/20 0.61
CCNE1 P24864 1/20 0.61
CDK2 P24941 1/20 0.61
CCNH P51946 1/20 0.61
MNAT1 P51948 1/20 0.61
CDK5R1 Q15078 1/20 0.61
ALK Q9UM73 7/20 0.60
RET P07949 6/20 0.60
FLT3 P36888 6/20 0.60
PDGFRB P09619 5/20 0.60
FGFR1 P11362 5/20 0.60
CSF1R P07333 4/20 0.60
FLT1 P17948 4/20 0.60
NTRK1 P04629 4/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6396125 1.00 KDR (0.64) KDRAURKBCDK7CDK5CDK1
SCHEMBL6388177 0.87 RET (0.60) KDRAURKBCDK7CDK5CDK1
SCHEMBL6388174 0.87 RET (0.60) KDRAURKBCDK7CDK5CDK1
SCHEMBL6396931 0.85 RET (0.62) KDRAURKBCDK5CDK1CCNB1
SCHEMBL6391259 0.85 RET (0.62) KDRAURKBCDK7CDK5CDK1
SCHEMBL6396929 0.85 RET (0.62) KDRAURKBCDK5CDK1CCNB1
SCHEMBL6407425 0.85 RET (0.62) KDRAURKBCDK7CDK5CDK1
SCHEMBL6407427 0.85 RET (0.62) KDRAURKBCDK7CDK5CDK1
SCHEMBL6391263 0.85 RET (0.62) KDRAURKBCDK7CDK5CDK1
SCHEMBL6396559 0.83 RET (0.55) KDRAURKBCDK7CDK5CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040024010-A1 3-methylidenyl-2-indolinone modulators of protein kinase SUGEN, INC. 2004-02-05 US claimed
US-6680335-B2 FOR THERAPY AND PROPHYLAXIS OF CANCER, HYPERTENSION, DEPRESSION, GENERALIZED ANXIETY DISORDER, PHOBIAS, POST-TRAUMATIC STRESS SYNDROME, AVOIDANT PERSONALITY DISORDER, SEXUAL DYSFUNCTION, EATING DISORDERS, OBESITY SUGEN, INC. 2004-01-20 US claimed
US-20020183364-A1 Methods of modulating protein tyrosine kinase function with substituted indolinone compounds SUGEN, INC. 2002-12-05 US claimed
WO-2000008202-A9 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE SUGEN INC (US) 2000-07-27 WO claimed
WO-2000008202-A2 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE SUGEN, INC. (US) 2000-02-17 WO claimed
US-20050203078-A1 Inhibitors of factor Xa or related serine proteases; thrombosis; benzamide derivatives with benzimidazole, indole or imidazo(1,2-a)pyridine rings; e.g. 4-(azepan-2-on-1-yl)-N-[(1R)-1-(5-chloro-1H-benzimidazol-2-yl)-2-methoxy-ethyl]-3-methyl-benzamide BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-09-15 US disclosed
US-6878733-B1 Formulations for pharmaceutical agents ionizable as free acids or free bases SUGEN, INC. (US) 2005-04-12 US disclosed
US-6855730-B2 3-methylidenyl-2-indolinone modulators of protein kinase SUGEN, INC. (US) 2005-02-15 US disclosed
US-20040024010-A1 3-methylidenyl-2-indolinone modulators of protein kinase SUGEN, INC. 2004-02-05 US disclosed
US-6680335-B2 FOR THERAPY AND PROPHYLAXIS OF CANCER, HYPERTENSION, DEPRESSION, GENERALIZED ANXIETY DISORDER, PHOBIAS, POST-TRAUMATIC STRESS SYNDROME, AVOIDANT PERSONALITY DISORDER, SEXUAL DYSFUNCTION, EATING DISORDERS, OBESITY SUGEN, INC. 2004-01-20 US disclosed
US-6531502-B1 Antitumor SUGEN, INC. 2003-03-11 US disclosed
US-20020183364-A1 Methods of modulating protein tyrosine kinase function with substituted indolinone compounds SUGEN, INC. 2002-12-05 US disclosed
WO-2000008202-A9 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE SUGEN INC (US) 2000-07-27 WO disclosed
WO-2000008202-A2 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE SUGEN, INC. (US) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024010-A1 3-methylidenyl-2-indolinone modulators of protein kinase DMPK, MAP4K3, MAP3K20 KDR 1617/4885AURKB 279/4885CDK7 344/4885
US-20020183364-A1 Methods of modulating protein tyrosine kinase function with substituted indolinone compounds PNCK, CAMK4, CAMK1 KDR 728/4885AURKB 346/4885CDK7 557/4885
US-20050203078-A1 Inhibitors of factor Xa or related serine proteases; thrombosis; benzamide derivatives with benzimidazole, indole or imidazo(1,2-a)pyridine rings; e.g. 4-(azepan-2-on-1-yl)-N-[(1R)-1-(5-chloro-1H-benzimidazol-2-yl)-2-methoxy-ethyl]-3-methyl-benzamide F12, TFPI, F11 KDR 1899/4885AURKB 1226/4885CDK7 1287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.